Abstract-Tissue nonspecific alkaline phosphatase, promoting arterial calcification in experimental models, is a powerful predictor of total and cardiovascular mortality in general population and in patients with renal or cardiovascular diseases. For this study, to evaluate a possible correlation between serum alkaline phosphatase levels and endothelial function, assessed by strain gauge plethysmography, we enrolled 500 naïve hypertensives divided into increasing tertiles of alkaline phosphatase. The maximal response to acetylcholine was inversely related to alkaline phosphatase (r=−0.55; P<0.001), and this association was independent (r=−0.61; P<0.001) of demographic and classical risk factors, body mass index, estimated glomerular filtration rate, serum phosphorus and calcium, C-reactive protein, and albuminuria. At multiple logistic regression analysis, the risk of endothelial dysfunction was ≈3-fold higher in patients in the third tertile than that of patients in the first tertile. We also tested the combined role of alkaline phosphatase and serum phosphorus on endothelial function. The steepness of the alkaline phosphatase/vasodilating response to acetylcholine relationship was substantially attenuated (P<0.001) in patients with serum phosphorus above the median value when compared with patients with serum phosphorus below the median (−5.0% versus −10.2% per alkaline phosphatase unit, respectively), and this interaction remained highly significant (P<0.001) after adjustment of all the previously mentioned risk factors. Our data support a strong and significant inverse relationship between alkaline phosphatase and endothelium-dependent vasodilation, which was attenuated by relatively higher serum phosphorus levels. (Hypertension. 2015;66:874-880.
T issue nonspecific alkaline phosphatase (ALP) is a highly expressed enzyme both in the liver and in the bone, which is routinely measured in clinical practice for the diagnosis and monitoring of hepatic and bony diseases. The main action of this enzyme is to catalyze the hydrolysis of the calcification inhibitor pyrophosphate. 1 Pivotal studies conducted in dialysis 2, 3 and in end-stage renal disease patients [4] [5] [6] demonstrated that ALP is linearly associated with all-cause and cardiovascular mortality, similarly to what also observed in patients without overt chronic kidney disease (CKD) 7, 8 ; in addition, a significant association between serum ALP and coronary heart disease and total mortality has been previously reported in older men. 9 Recent data showed that mild inflammation and oxidative stress signaling play a key pathogenetic role in the development of vascular mineral deposition of which ALP is a wellestablished marker. [10] [11] [12] Interestingly, growing evidences have clearly demonstrated that endothelial dysfunction, an early event in the atherosclerotic process, [13] [14] [15] [16] [17] is multifactorial, involving many conditions leading to an increased oxidative stress and subclinical inflammation. 18, 19 Notably, previously published data demonstrated that endothelial dysfunction, independently of classical risk factors, is a strong and independent predictor of cardiovascular events in different clinical conditions, 17 including essential hypertension. 20 However, at this time, no data are available on a possible association between serum ALP and endothelial dysfunction. Therefore, testing whether ALP affects endothelial function in hypertensive subjects is a relevant question to expand knowledge on its potential role in the pathogenesis of cardiovascular diseases. Thus, we designed this study to evaluate (1) a possible correlation between serum ALP levels and endothelium-dependent vasodilation, assessed by strain gauge plethysmography, in a large population of newly diagnosed never-treated hypertensive patients, (2) the combined role of ALP and serum phosphorus (sP) on endothelial function, given their close link in bone metabolism both in patients with CKD and in normal subjects, and the emerging conflicting evidences about sP as a nontraditional cardiovascular risk factor.
Methods
We recruited 500 white hypertensive outpatients (256 men and 244 women; mean age, 47.2+11.0 years) referred to the Hypertension Clinic of the University Hospital of Catanzaro. All patients had a normal renal function evaluated by estimated glomerular filtration rate (eGFR) >60 mL/min per 1.73 m 2 . None of the patients had a history or clinical evidence of angina, myocardial infarction, valvular heart disease, diabetes mellitus, hypercholesterolemia, peripheral vascular disease, advanced liver diseases or alterations in serum glutamic oxaloacetic transaminase and γ-glutamyl transpeptidase, calciumphosphorus metabolism disorders, coagulopathies, or any disease predisposing to vasculitis or Raynaud phenomenon. Other exclusion criteria were history of alcohol, drug abuse, and the use of drugs interfering with sP concentrations. Secondary forms of hypertension were excluded by systematic testing according to a standard clinical protocol. 20 At the time of the first evaluation, we performed routine blood tests, assessment of atherosclerosis risk factors, and evaluation of vascular function.
High-sensitivity C-reactive protein (hs-CRP) was measured by a turbidimetric immunoassay (Behring) in 400 patients, who were comparable with the whole study population with regard to the variables listed in Table 1 . The local Ethics Committee approved the study, and all participants gave written informed consent for all procedures.
ALP, Phosphorus, and Markers of Renal Function
Serum ALP (normal range, 40-129 IU/L) and calcium (normal range, 8.5-10.3 mg/dL) levels were measured in fasting participants with standard assays implemented on the COBAS C501 Roche auto-analyzer.
The quantitative concentration of inorganic sP (normal range, 2.3-4.5 mg/dL) was measured by spectrophotometric determination based on the formation of ammonium molybdophosphate with subsequent reduction to molybdenum blue, using the diagnostic assay COBAS INTEGRA Phoshate 2 (Roche diagnostics).
Serum creatinine was measured in the routine laboratory by use of the Jaffe methodology and the uricase peroxidase (uricase/POD; Boehringer Mannheim, Mannheim, Germany) method implemented in an auto-analyzer. Values of eGFR were calculated with the new equation CKD-Epidemiology Collaboration. 28 Microalbuminuria was measured by a turbidimetric inhibition immunoassay (Boehringer Mannheim). Patients with available microalbuminuria and hs-CRP measurements were comparable with the whole study population with regard to the variables listed in Table 1 .
Forearm Blood Flow Measurement
All studies were performed at 09:00 am after an overnight fast with the subjects lying supine in a quiet, air-conditioned room (22°C-24°C). Subjects continued their regular diet and were asked to refrain from alcohol and smoking for 24-hour before the test. Forearm volume was determined by water displacement. Under local anesthesia and sterile conditions, a 20-gauge polyethylene catheter (Vasculon 2; Baxter Healthcare, Deerfield, IL) was inserted into the brachial artery of the nondominant arm for evaluation of blood pressure (BP) and for drug infusion. This arm was elevated slightly above the right atrium, and a mercury-filled Silastic strain gauge was placed on the widest part of the forearm. The strain gauge was connected to a plethysmograph (model EC-4; DE Hokanson, Issaquah, WA) calibrated to measure the percent change in volume; this was connected to a chart recorder to obtain forearm blood flow (FBF) measurements. A cuff placed on the upper arm was inflated to 40 mm Hg with a rapid cuff inflator (model E-10; DE Hokanson) to exclude venous outflow from the extremity. FBF was measured as the slope of the change in forearm volume; the mean of 3 measurements was obtained at each time point. 
Vascular Function
We used the protocol described by Panza et al 29 and subsequently used by us. 19, 20, 30, 31 All patients underwent measurement of FBF and BP during intra-arterial infusion of saline, acetylcholine, and sodium nitroprusside (SNP) at increasing doses. All participants rested 30 minutes after artery cannulation to reach a stable baseline before data collection; measurements of FBF and vascular resistance were repeated every 5 minutes until stable. Endothelium-dependent and endothelium-independent vasodilation was assessed by a doseresponse curve to intra-arterial acetylcholine infusions (7.5, 15, and 30 μg/mL per minute, each for 5 minutes) and SNP infusions (0.8, 1.6, and 3.2 μg/mL per minute, each for 5 minutes), respectively. Acetylcholine (Sigma, Milan, Italy) was diluted with saline immediately before infusion. SNP (Malesci, Florence, Italy) was diluted in 5% glucose solution immediately before each infusion and protected from light with aluminum foil.
Statistical Analysis
Data are expressed as mean±SD or as percent frequency; comparisons between groups were made by P for trend. Relationships between paired parameters were analyzed by Pearson correlation coefficient. The independent relationship between the response to acetylcholine and ALP was modeled in analyses (either multiple linear or logistic regression) of increasing complexity (ie, in models including all univariate correlates of the response to acetylcholine and in models including all risk factors listed in Table 1 ). Tested covariates included traditional risk factors (age, sex, smoking, body mass index, BP, heart rate, lipids, and glucose), sP, calcium, and eGFR. The potential effect of hs-CRP (n=400) and albuminuria (n=164) was tested in subgroups of patients in whom such risk factors were available. The potential effect modification by covariates was tested by introducing a multiplicative term into the model to detect a possible competitive interaction exerted by sP on the linear relationship between ALP and the acetylcholine-stimulated FBF. In multiple linear regression models, data were expressed as unstandardized regression coefficients (slopes), standardized regression coefficient (β), and P value. In multiple logistic regression analyses, data were expressed as odds ratio, 95% confidence interval, and P value. All calculations were made with a standard statistical package (SPSS for Windows version 20.0).
Results
Serum ALP values in the study population ranged from 39 Table 1 . There were no significant differences in any of the variables among tertiles with the exclusion of sP, eGFR, and acetylcholine peak percent increase. In fact, the maximal vasodilating response to acetylcholine was significantly reduced from first to third tertile of ALP. All patients showed a normal endothelium-independent vasodilation to SNP infusions, without any significant difference among groups.
In univariate analyses, ALP was the strongest correlate of the maximal FBF response to acetylcholine (Table 2) 
Multivariate Analyses
To test the independent association between ALP and other covariates with the maximal acetylcholine-stimulated FBF, we performed multiple linear regression analyses of different Table 3 , ALP coherently ranked as the strongest independent correlate of the response to acetylcholine. In analyses, restricted to patients with available hs-CRP and albuminuria data, the link between ALP and the acetylcholinestimulated FBF remained highly significant (b=−0.31; P<0.001).
To estimate the odds of endothelial dysfunction (ie, FBF peak percent increase <400%) associated with ALP levels, we performed a multiple logistic regression analysis (Table 4) . In this analysis, the risk of endothelial dysfunction was ≈3-fold higher in patients in the third ALP tertile than that of patients in the first tertile (Table 4 ). In the same model, every 1 U/L increase in ALP expressed as a continuous variable caused a 6% risk excess (odds ratio=1.06; 95% confidence interval, 1.04-1.08; P<0.001) for endothelial dysfunction.
Effect Modification by sP on the Relationship Between ALP and FBF
Because the strong inter-relationship between ALP and sP ( Figure 1, left) and their parallel association with the maximal FBF response to acetylcholine (Table 2; Figure 1 , right), we tested whether these 2 variables interact in explaining the variability of the maximal acetylcholine-stimulated FBF. In this analysis (Table 3 , model 3; Figure 2 ), a strong competitive interaction emerged between sP (below/above the median value) and ALP levels. Indeed, the slope of the ALP/ vasodilating response to acetylcholine was much steeper in patients with relatively lower sP levels (empty circles) than that of patients with relatively higher sP levels (dark circles). The same effect modification was confirmed in a multiple linear regression model ( Table 3 ), demonstrating that for 1 U/L increase in ALP there was a 10.2% and a 5.0% reduction in the maximal FBF response in patients with sP below and above the median, respectively (Figure 2 ). These findings suggest that relatively higher sP levels may attenuate the detrimental effect of ALP on endothelium-dependent vasodilatation.
Discussion
For the first time, in this cross-sectional study, we demonstrated that in uncomplicated and untreated essential hypertensives, endothelium-dependent vasodilation was inversely related with serum ALP values within the normal range. Interestingly, this association was largely independent of classical cardiovascular and other emerging risk factors, such as hs-CRP, eGFR, and albuminuria, all factors associated per se with serum ALP levels as previously reported. 32, 33 In addition, at logistic regression analysis, we observed that the risk of endothelial dysfunction increased across tertiles of serum ALP levels; in fact, the odds ratios for hypertensive patients in the second and third tertiles were 2.53 (95% confidence interval, 1.65-3.89) and 3.05 (95% confidence interval, 1.91-4.87).
Furthermore, another important finding provided by this study is the interplay between sP levels and ALP in modulating endothelium-dependent vasodilation. Particularly, the FBF impairment sP related is about doubled (10.2% versus 5.0% for each 1 U/L ALP increase) when sP levels are below the median (Figure 2 ). These observations allow to extend previous knowledge about the complex pathogenetic mechanism of atherosclerosis and to focus on the possible role of ALP in this pathway in the specific setting of essential, uncomplicated, never-treated hypertension, as well as in other cardiovascular conditions. This interaction generates the hypothesis that sP is a relevant modulator of the biological effects of ALP on endothelial function; particularly, our data demonstrate that even if in the normal range, relatively higher sP levels attenuate the negative effect of ALP on endothelial function. This finding builds the hypothesis of a possible hierarchical role of sP upon ALP on the appearance of vascular damage or, alternatively, an interplay between them on a common pathogenetic pathway leading to endothelial dysfunction. Overall, our findings add novel perspectives in the interpretation of the mechanisms underlying the association between ALP and cardiovascular events, suggesting that the endothelium may be an early target of raised ALP. At this regard, our study lacks mechanistic insight why serum ALP may induce endothelial dysfunction. The mild subclinical inflammation may be recognized as a possible pathogenetic mechanism, as reported by previously published data, [10] [11] [12] 34 but not confirmed by our results. Serum ALP has been associated with markers of vascular function and BP in 2 studies in the general population. The first study, 33 conducted in 5995 individuals aged >40 years enrolled in the US National Health and Nutrition Examination Survey, demonstrated an inverse relationship between ALP and the ankle-brachial index, independently of classical cardiovascular risk factors. In the second, 35 ALP was associated, in a series of 101 unselected African men independently of other risk factors, with carotid intima-media thickness and with 24-hour systolic BP and pulse pressure. In addition, recent analyses by structural equations modeling in 3773 subjects in the National Health and Nutrition Examination Survey database 32 showed that ALP is a key mediator in the pathogenetic pathway of vascular calcification in type 2 diabetic patients or metabolic syndrome. ALP hydrolyzes pyrophosphate, a potent calcification inhibitor, thereby favoring calcium salts deposition at tissue level. 36, 37 Inhibition of ALP activity was able to reduce calcifications in vascular smooth muscle cells in the NPP1 (ecto-nucleotide pyrophosphatase/phosphodiesterases-1) and ANK (ankyrin)-deficient mice, 38 an experimental model characterized by extensive aortic calcification. Thus, ALP may be an active player in human atherosclerosis, a hypothesis in line with observational We graphically reported the competitive interaction between serum phosphorus (below/above the median value) and alkaline phosphatase (ALP) levels. The slope of the ALP/ vasodilating response to acetylcholine (ACh) was much steeper in patients with relatively lower serum phosphorus levels (empty circles) than that of patients with relatively higher phosphorus levels (dark circles). This effect was confirmed in a multiple linear regression model demonstrating that for 1 U/L increase in ALP, there was a 10.2% and a 5.0% reduction in the maximal forearm blood flow response in patients with serum phosphorus below and above the median, respectively.
by guest on July 11, 2017 http://hyper.ahajournals.org/ Downloaded from studies linking this molecule with mortality and cardiovascular events in patients with [4] [5] [6] or without 7, 8 CKD. Taken together, our data are particularly relevant because they demonstrate, for the first time, a significant association between ALP and endothelial dysfunction, an early functional alteration in the continuum of vascular aging and atherosclerotic process. Thus, even if present data do not allow to identify a mechanistic effect between ALP levels and endothelium-mediated vasodilation, consent is to consider ALP as an early biomarker in detecting vascular damage when this alteration is still functional and potentially modifiable.
Interestingly, given the lack of association between ALP and the vasodilating response to SNP, it is plausible that this relationship involves specific pathogenetic mechanisms operating on endothelium-dependent vasodilatation rather than being an unspecific response to vasodilatory stimuli acting on vascular smooth muscle cells.
Although high levels of ALP were associated with vascular damage, as peripheral artery disease 33 or the increase of intima-media thickness, 35 and the increase in vascular calcifications, 32 it is currently not possible to recognize a clear pathogenetic mechanism linking ALP to endothelial dysfunction. There are some possible explanations for our findings. First, it is possible to hypothesize that ALP reduces nitric oxide (NO) bioavailability by inhibiting tyrosine kinase activity into endothelial cells 39 with consequent impairment of endothelial NO synthase function and reduction of NO production. 40 Second, high ALP levels, as consequence of the increased degradation of pyrophosphate, may impair endothelial function promoting high production of reactive oxygen species and apoptosis. 41 Additional possible explanation of our findings is that ALP is a surrogate of high fibroblast growth factor-23 levels, a bone-derived hormone implicated in the regulation of mineral metabolism, that resulted in association with endothelial function in individuals with both normal and impaired renal function. 42 This association may be explained by data derived from Klotho null mice, which carry no functional fibroblast growth factor-23 activity because of lack of coreceptors. 43, 44 Whether the associations unraveled by the present study underlie a causal mechanism implicated in atherosclerosis should be tested in appropriate longitudinal studies and in clinical trials.
Limitations
(1) The cross-sectional design that does not allow establishment of the direction of causality; our observations remain to be confirmed in prospective observational and interventional studies. (2) Ours is a tertiary referral center, and, therefore, patients of this study are a selected population not representative of primary care. (3) We did not measure the main factors regulating mineral balance, such as serum parathyroid hormone, vitamin D, and fibroblast growth factor-23. However, the large study population, the careful selection of patients without liver disease or excessive alcohol intake, and the fact that measurements of ALP and other biomarkers were made in a single laboratory, all represent strengths of the study. (4) Finally, we did not measure either oxidative stress or NO levels.
Conclusions
Our data support, in a large cohort of hypertensive patients, a strong and significant inverse relationship between ALP levels and endothelium-dependent vasodilation that was attenuated by relatively higher sP levels. These findings need to be confirmed in other studies measuring the full set of CKD, body mineral disorders biomarkers, and adipose tissue cytokines implicated in the control of vascular function. Hence, given the availability and low cost of serum ALP assays, our findings may prove clinically useful to detect possible vascular damage in an early step.
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What Is New?
• This study demonstrates, for the first time, that alkaline phosphatase (ALP) values in the normal range negatively affect endothelium-dependent vasodilation in the setting of uncomplicated, untreated, essential hypertension, independently of other traditional and emerging cardiovascular risk factors. Moreover, we observed that relatively higher phosphorus levels attenuate the detrimental effect of ALP on endothelial function.
What Is Relevant?
• Our results contribute to expand previous knowledge about the pathogenetic mechanism of atherosclerosis, particularly focusing on the interplay between serum phosphorus and ALP, acting on a common pathway. Overall, our findings add novel perspectives in the interpretation of the mechanisms underlying the association between ALP and cardiovascular events, suggesting that the endothelium may be an early target of raised ALP.
Summary
In 500 naïve hypertensives, we demonstrated that ALP is inversely related with endothelium-dependent vasodilation, evaluated by strain gauge plethysmography, independently of demographic and classical cardiovascular risk factors. In addition, our data also demonstrated that this relationship was attenuated by relatively higher serum phosphorus levels, suggesting a strong interaction between them.
